Unlocking the Next Generation of Reporting and Analytics for Drug Safety Intelligence
The Future of Drug Safety Intelligence The future of safety ...
Madrid, Spain
10 – 11 Feb 2026
Operationalizing AI: Turning proven AI use cases into everyday practice across life sciences.
The Future of Drug Safety Intelligence The future of safety ...
The coronavirus pandemic ushered in a new era of public ...
Organizations currently utilizing manual pharmacovigilance processing understand that it involves many time-consuming manual activities, but ArisGlobal’s LifeSphere Multivigilance 10 is the future of pharmacovigilance.
As part of our commitment to providing the most robust ...
The DIA 2020 Annual Meeting Is Now Virtual. ArisGlobal will be front and center with presentations covering both Safety and Clinical perspectives in Life Sciences process management.
On November 28, 2017, ArisGlobal held a webinar with DIA, “How Automation Can Deliver the Holy Grail in Safety: Achieve Productivity, Compliance and Quality”. In this webinar, we posed a few questions to the audience, and came up with some interesting information. We took this and spent some thinking about what this means to our clients in the PV ecosystem.
Advanced computing methods can be used for safety monitoring and early detection of potential signals of vaccine-related adverse events. These methods work by mining open-access active-moiety databases and vast scientific literature with clinical case studies.
What will the next generation of reporting and analytics in ...
This is the second in a three-part blog series on National Pharmacovigilance systems and the role of technology in bridging the gaps in pharmacovigilance of regulatory authorities around the world.
Life sciences companies confront increasingly stringent requirements on safety signal detection and risk management. Regulatory authorities are taking steps to further safeguard patients by requiring companies to take more comprehensive steps to assess and monitor the benefit-risk balance of their products.
ArisGlobal is a pivotal partner in the life sciences industry, specializing in solutions that drive drug development, safety monitoring, and regulatory compliance. We collaborate with more than 220 global life sciences companies, CROs, and government health authorities, including leading biopharmaceutical firms and regulatory bodies such as FDA, Health Canada, and NMPA.
Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan and China.
Quick Links
© 2024 ArisGlobal – All Rights Reserved